What is Pierian Biosciences?
Pierian Biosciences operates at the intersection of advanced laboratory services and personalized cancer intelligence. By leveraging proprietary multi-parametric chemosensitivity assays and functional immuno-assays, the company provides healthcare providers with the critical insights necessary to tailor therapeutic interventions for complex cancer and auto-immune conditions. Their commitment to translational science bridges the gap between laboratory discovery and bedside application, positioning them as a pivotal player in the evolution of precision medicine. Through these innovative analytical approaches, Pierian Biosciences enables a more nuanced understanding of patient-specific disease profiles, ultimately driving improved clinical outcomes and more efficient treatment selection protocols.
How much funding has Pierian Biosciences raised?
Pierian Biosciences has raised a total of $314K across 2 funding rounds:
Debt
$150K
Debt
$164K
Debt (2020): $150K with participation from PPP
Debt (2021): $164K led by PPP
Key Investors in Pierian Biosciences
PPP
Public-Private Partnership
What's next for Pierian Biosciences?
With the infusion of this latest capital, Pierian Biosciences is well-positioned to accelerate its operational expansion and deepen its research and development pipeline. The company is expected to focus on scaling its diagnostic platforms to meet the growing demand for personalized treatment-directing assays. By enhancing its laboratory infrastructure and broadening its reach within the healthcare ecosystem, Pierian aims to solidify its role as a leader in diagnostic innovation. Future growth will likely center on the commercialization of its functional immuno-assay technology and the integration of its diagnostic services into broader clinical workflows, ensuring that clinicians have the tools required to navigate the complexities of modern oncology and autoimmune disease management.
See full Pierian Biosciences company page
